STAAR Surgical (NASDAQ:STAA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

STAAR Surgical (NASDAQ:STAA) released its earnings results on Wednesday. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.06), FiscalAI reports. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.53 million for the quarter, compared to analysts’ expectations of $90.60 million.

Here are the key takeaways from STAAR Surgical’s conference call:

• Record first-half performance: Second-quarter revenue rose 111% year over year to $93.5 million, supported by sequential growth in China and double-digit growth across the Americas and EMEA excluding the Middle East.
• Profitability and cash flow improved materially. Net income reached $8.1 million versus a $16.8 million loss a year earlier, adjusted EBITDA was $20 million, and cash increased to $181.5 million with no debt; management expects to end 2026 with more than $200 million in cash.
• EVO+ is gaining traction in China and driving market-share gains. China revenue grew 10% sequentially to $52.3 million, EVO+ represented nearly one-third of units exiting the quarter, and the product commanded a premium without apparent customer resistance, although supply remains constrained.
• Near-term comparisons and operating headwinds remain significant. Third-quarter 2025 included a nonrecurring $25.9 million order, China is expected to be seasonally lower than the second quarter, and tariffs on U.S.-manufactured products will pressure margins until shipments to China are fully produced in Switzerland, targeted by the end of 2026.
• STAAR is broadening its innovation strategy beyond EVO. The company is preparing for first-in-human studies of next-generation products and plans to hire a chief technology officer to develop a broader, Collamer-centered ophthalmology platform.

STAAR Surgical Stock Performance

Shares of NASDAQ STAA traded up $0.47 during trading on Wednesday, reaching $25.41. 1,334,390 shares of the company traded hands, compared to its average volume of 1,188,711. The stock has a market cap of $1.27 billion, a P/E ratio of -59.09 and a beta of 1.26. The firm’s fifty day simple moving average is $27.03 and its 200 day simple moving average is $24.04. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on STAA shares. Weiss Ratings upgraded STAAR Surgical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 25th. Piper Sandler lifted their target price on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Canaccord Genuity Group upped their target price on STAAR Surgical from $27.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Wells Fargo & Company increased their price target on shares of STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. Finally, Stifel Nicolaus raised their price target on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, STAAR Surgical presently has a consensus rating of “Hold” and a consensus price target of $26.94.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after purchasing an additional 1,267 shares during the period. Goldman Sachs Group Inc. increased its holdings in STAAR Surgical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after buying an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock worth $2,175,000 after acquiring an additional 12,841 shares during the period. Creative Planning raised its position in shares of STAAR Surgical by 19.9% in the second quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock worth $263,000 after acquiring an additional 2,606 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of STAAR Surgical by 183.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock worth $2,574,000 after acquiring an additional 99,218 shares in the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.